N R Lemoine

Summary

Affiliation: Cancer Research UK
Country: UK

Publications

  1. pmc Silencing RNA: a novel treatment for pancreatic cancer?
    N R Lemoine
    Cancer Research UK Molecular Oncology Unit, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, London EC1 6BQ, UK
    Gut 54:1215-6. 2005
  2. pmc Identification of genetic alterations in pancreatic cancer by the combined use of tissue microdissection and array-based comparative genomic hybridisation
    T Harada
    Centre for Molecular Oncology, Institute of Cancer, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK
    Br J Cancer 96:373-82. 2007
  3. pmc Gene transfer: Bax to the future for cancer therapy
    N R Lemoine
    Cancer Research UK Clinical Centre, Sir John Vane Science Building, Barts and the London School of Medicine and Dentistry, London, UK
    Gut 53:478-9. 2004
  4. pmc Pancreatic Expression database: a generic model for the organization, integration and mining of complex cancer datasets
    Claude Chelala
    Centre for Molecular Oncology, Institute of Cancer and CR UK Clinical Centre, Barts and The London School of Medicine QMUL, Charterhouse Square London EC1M 6BQ, UK
    BMC Genomics 8:439. 2007
  5. doi request reprint Yes-associated protein (YAP) functions as a tumor suppressor in breast
    M Yuan
    Cell Survival Signalling Laboratory, Centre for Molecular Oncology, Institute of Cancer, Charterhouse Square, London, UK
    Cell Death Differ 15:1752-9. 2008
  6. ncbi request reprint Survivin interacts with Smac/DIABLO in ovarian carcinoma cells but is redundant in Smac-mediated apoptosis
    I A McNeish
    Cancer Research UK Molecular Oncology Unit, Barts and the London School of Medicine, London EC1M 6BQ, United Kingdom
    Exp Cell Res 302:69-82. 2005
  7. pmc Genome-wide DNA copy number analysis in pancreatic cancer using high-density single nucleotide polymorphism arrays
    T Harada
    Centre for Molecular Oncology, Cancer Research UK, Institute of Cancer, Barts and the London School of Medicine and Dentistry, Queen Mary, University of London, London, UK
    Oncogene 27:1951-60. 2008
  8. doi request reprint An oncolytic adenovirus defective in pRb-binding (dl922-947) can efficiently eliminate pancreatic cancer cells and tumors in vivo in combination with 5-FU or gemcitabine
    M Bhattacharyya
    Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK
    Cancer Gene Ther 18:734-43. 2011
  9. pmc Oncolytic adenoviral mutants induce a novel mode of programmed cell death in ovarian cancer
    S K Baird
    Centre for Molecular Oncology, Cancer Research UK Clinical Centre, Institute of Cancer, Barts and the London Queen Mary s School of Medicine, London, UK
    Oncogene 27:3081-90. 2008
  10. ncbi request reprint Periostin promotes invasiveness and resistance of pancreatic cancer cells to hypoxia-induced cell death: role of the beta4 integrin and the PI3k pathway
    P Baril
    Centre for Molecular Oncology, Institute of Cancer and the CR UK Clinical Centre, Barts, UK
    Oncogene 26:2082-94. 2007

Collaborators

Detail Information

Publications52

  1. pmc Silencing RNA: a novel treatment for pancreatic cancer?
    N R Lemoine
    Cancer Research UK Molecular Oncology Unit, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, London EC1 6BQ, UK
    Gut 54:1215-6. 2005
  2. pmc Identification of genetic alterations in pancreatic cancer by the combined use of tissue microdissection and array-based comparative genomic hybridisation
    T Harada
    Centre for Molecular Oncology, Institute of Cancer, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK
    Br J Cancer 96:373-82. 2007
    ..Our results raise the possibility that the SEC11L3 gene may play a role as a tumour suppressor in this disease...
  3. pmc Gene transfer: Bax to the future for cancer therapy
    N R Lemoine
    Cancer Research UK Clinical Centre, Sir John Vane Science Building, Barts and the London School of Medicine and Dentistry, London, UK
    Gut 53:478-9. 2004
  4. pmc Pancreatic Expression database: a generic model for the organization, integration and mining of complex cancer datasets
    Claude Chelala
    Centre for Molecular Oncology, Institute of Cancer and CR UK Clinical Centre, Barts and The London School of Medicine QMUL, Charterhouse Square London EC1M 6BQ, UK
    BMC Genomics 8:439. 2007
    ....
  5. doi request reprint Yes-associated protein (YAP) functions as a tumor suppressor in breast
    M Yuan
    Cell Survival Signalling Laboratory, Centre for Molecular Oncology, Institute of Cancer, Charterhouse Square, London, UK
    Cell Death Differ 15:1752-9. 2008
    ..This is the first report indicating YAP as a tumor suppressor, revealing its decreased expression in breast cancer as well as demonstrating the functional implications of YAP loss in several aspects of cancer signaling...
  6. ncbi request reprint Survivin interacts with Smac/DIABLO in ovarian carcinoma cells but is redundant in Smac-mediated apoptosis
    I A McNeish
    Cancer Research UK Molecular Oncology Unit, Barts and the London School of Medicine, London EC1M 6BQ, United Kingdom
    Exp Cell Res 302:69-82. 2005
    ..We believe that expression of Smac/DIABLO can stimulate the intrinsic pathway of apoptosis in ovarian carcinoma without damaging normal ovarian tissue and therefore has therapeutic potential...
  7. pmc Genome-wide DNA copy number analysis in pancreatic cancer using high-density single nucleotide polymorphism arrays
    T Harada
    Centre for Molecular Oncology, Cancer Research UK, Institute of Cancer, Barts and the London School of Medicine and Dentistry, Queen Mary, University of London, London, UK
    Oncogene 27:1951-60. 2008
    ..001). These findings indicate that the dysregulation of SKAP2/SCAP2, which is mostly caused by its increased gene copy number, is likely to be associated with the development of PDAC...
  8. doi request reprint An oncolytic adenovirus defective in pRb-binding (dl922-947) can efficiently eliminate pancreatic cancer cells and tumors in vivo in combination with 5-FU or gemcitabine
    M Bhattacharyya
    Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK
    Cancer Gene Ther 18:734-43. 2011
    ..We demonstrate that dl922-947 is highly efficacious in pancreatic cancers and conclude that oncolytic adenoviruses harboring the E1ACR2 deletion have great potential for development into future clinical candidates for pancreatic cancer...
  9. pmc Oncolytic adenoviral mutants induce a novel mode of programmed cell death in ovarian cancer
    S K Baird
    Centre for Molecular Oncology, Cancer Research UK Clinical Centre, Institute of Cancer, Barts and the London Queen Mary s School of Medicine, London, UK
    Oncogene 27:3081-90. 2008
    ..6 does not modulate the mode or extent of cell death. Thus, E1A CR2-deleted oncolytic adenoviral cytotoxicity in ovarian cancer may define a novel mode of programmed cell death...
  10. ncbi request reprint Periostin promotes invasiveness and resistance of pancreatic cancer cells to hypoxia-induced cell death: role of the beta4 integrin and the PI3k pathway
    P Baril
    Centre for Molecular Oncology, Institute of Cancer and the CR UK Clinical Centre, Barts, UK
    Oncogene 26:2082-94. 2007
    ..These findings suggest an important role of periostin in pancreatic cancer and provide a rationale to study periostin for diagnostic and therapeutic applications...
  11. doi request reprint Targeting sodium/iodide symporter gene expression for estrogen-regulated imaging and therapy in breast cancer
    C A Montiel-Equihua
    Centre for Molecular Oncology, Institute of Cancer and CR UK Clinical Centre, Barts and The London, School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, London, UK
    Cancer Gene Ther 15:465-73. 2008
    ..In vivo, we show that AdSERE-infected ER+ tumors can be imaged due to tracer accumulation; in addition, AdSERE in combination with therapeutic doses of (131)I suppresses tumor growth...
  12. doi request reprint The oncolytic adenovirus AdΔΔ enhances selective cancer cell killing in combination with DNA-damaging drugs in pancreatic cancer models
    G Cherubini
    Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK
    Gene Ther 18:1157-65. 2011
    ..We conclude that AdΔΔ has low toxicity to normal cells while potently sensitizing pancreatic cancer cells to DNA-damaging drugs, and holds promise as an improved therapeutic strategy for pancreatic cancer...
  13. pmc E1A-expressing adenoviral E3B mutants act synergistically with chemotherapeutics in immunocompetent tumor models
    S C Cheong
    Centre for Molecular Oncology, Institute of Cancer, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK
    Cancer Gene Ther 15:40-50. 2008
    ..Our results suggest that the attenuation of DeltaE3B mutants can be overcome by low doses of chemotherapeutics only in the presence of an intact immune response indicating a role for T-cell-mediated functions...
  14. pmc Lister strain of vaccinia virus armed with endostatin-angiostatin fusion gene as a novel therapeutic agent for human pancreatic cancer
    J R Tysome
    Centre for Molecular Oncology and Imaging, Institute of Cancer, Barts and the London School of Medicine and Dentistry, London, UK
    Gene Ther 16:1223-33. 2009
    ..t. administration. This study suggests that the novel Lister strain of vaccinia virus armed with the endostatin-angiostatin fusion gene is a potential therapeutic agent for pancreatic cancer...
  15. ncbi request reprint Sperm-associated antigen 1 is expressed early in pancreatic tumorigenesis and promotes motility of cancer cells
    A Neesse
    Cancer Research UK Molecular Oncology Unit, Barts and the London School of Medicine and Dentistry, Queen Mary s University, John Vane Science Building, Charterhouse Square, London, UK
    Oncogene 26:1533-45. 2007
    ..Combined with the finding of its early expression in PDAC development, our data suggest that SPAG1 could contribute to the early spread and poor prognosis of pancreatic adenocarcinoma...
  16. pmc Lister strain vaccinia virus, a potential therapeutic vector targeting hypoxic tumours
    C T Hiley
    Centre for Molecular Oncology and Imaging, Institute of Cancer, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK
    Gene Ther 17:281-7. 2010
    ..The present study suggests that the vaccinia virus is a promising vector for targeting pancreatic cancer and potentially other hypoxic tumour types...
  17. ncbi request reprint Potential therapeutic applications of recombinant, invasive E. coli
    R J Critchley
    Cancer Research UK Molecular Oncology Unit, ICSM at Hammersmith Hospital, London, UK
    Gene Ther 11:1224-33. 2004
    ..This therapeutic effect is associated with infiltration of neutrophils, eosinophils, macrophages and to a lesser extent dendritic cells in the tumour mass...
  18. ncbi request reprint Functional interactions of antiapoptotic proteins and tumor necrosis factor in the context of a replication-competent adenovirus
    T C Liu
    Viral and Genetic Therapy Program, Cancer Research UK Molecular Oncology Unit, Barts and The London School of Medicine and Imperial College Faculty of Medicine, Hammersmith Hospital, London, UK
    Gene Ther 12:1333-46. 2005
    ..In addition, functional redundant viral genes and their biological mediators/targets need to be carefully examined for the next generation of gene-deleted oncolytic viruses...
  19. pmc Expression of the ERBB3 gene product in breast cancer
    N R Lemoine
    ICRF Oncology Group, Royal Postgraduate Medical School, Hammersmith Hospital, London, UK
    Br J Cancer 66:1116-21. 1992
    ..High expression of ERBB3 is positively associated with the presence of lymph node metastases, but there was no demonstrable relationship with patient survival in this series...
  20. ncbi request reprint Gene expression profiles of pancreatic cancer and stromal desmoplasia
    T Crnogorac-Jurcevic
    Imperial Cancer Research Fund Molecular Oncology Unit, Imperial College School of Medicine at Hammersmith Campus, London, UK
    Oncogene 20:7437-46. 2001
    ....
  21. ncbi request reprint A recombinant E. coli vaccine to promote MHC class I-dependent antigen presentation: application to cancer immunotherapy
    K J Radford
    Cancer Research UK, Molecular Oncology Unit, ICSM at Hammersmith Hospital, London, UK
    Gene Ther 9:1455-63. 2002
    ..coli LLO/OVA provided an even stronger anti-tumour response against B16-OVA. Altogether, our data highlight the potential of this system as a novel and efficient strategy for tumour immunotherapy...
  22. pmc Expression of growth factor receptors in human brain tumours
    N L Tuzi
    ICRF Oncology Group, Hammersmith Hospital, London, UK
    Br J Cancer 63:227-33. 1991
    ..There was however no evidence for aberrant expression of the c-erbB-2 protein. Additional experiments are required to assess the influence of PDGF receptor expression in brain tumour cells...
  23. ncbi request reprint Gene therapy progress and prospects: cancer gene therapy using tumour suppressor genes
    I A McNeish
    Cancer Research UK, Molecular Oncology Unit, Imperial College School of Medicine, Hammersmith Hospital, London, UK
    Gene Ther 11:497-503. 2004
    ....
  24. pmc Antisense oligonucleotides directed against p53 have antiproliferative effects unrelated to effects on p53 expression
    C M Barton
    Imperial Cancer Research Fund Oncology Unit, Hammersmith Hospital, London, UK
    Br J Cancer 71:429-37. 1995
    ..These findings suggest that the antiproliferative effects of some antisense oligonucleotides may be unrelated to expression of the gene they have been designed to target...
  25. ncbi request reprint Abnormalities of the EGF receptor system in human thyroid neoplasia
    N R Lemoine
    Molecular Pathology Laboratory, Royal Postgraduate Medical School, Hammersmith Hospital, London, UK
    Int J Cancer 49:558-61. 1991
    ..We conclude that there is a potential autocrine loop involving the EGF-r system in both neoplastic and non-neoplastic conditions of the human thyroid...
  26. doi request reprint Lister strain vaccinia virus with thymidine kinase gene deletion is a tractable platform for development of a new generation of oncolytic virus
    J Hughes
    Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK
    Gene Ther 22:476-84. 2015
    ..This study indicates that the Lister strain VVΔTK may be a particularly promising VV strain for the development of the next generation of tumor-targeted oncolytic therapeutics. ..
  27. pmc Characterisation of human thyroid epithelial cells immortalised in vitro by simian virus 40 DNA transfection
    N R Lemoine
    ICRF Molecular Oncology Group, Hammersmith Hospital, London, UK
    Br J Cancer 60:897-903. 1989
    ..These differentiated, These differentiated, partially transformed cell lines were shown to be suitable for gene transfer at high frequency using simple coprecipitation techniques...
  28. ncbi request reprint Characterisation of LMD virus-like nanoparticles self-assembled from cationic liposomes, adenovirus core peptide mu and plasmid DNA
    T Tagawa
    Imperial College Genetic Therapies Centre, Department of Chemistry, Imperial College of Science, Technology and Medicine, London, UK
    Gene Ther 9:564-76. 2002
    ..All these features make LMD an important new non-viral vector platform system from which to derive tailor-made non-viral delivery systems by a process of systematic modular upgrading...
  29. ncbi request reprint Progress and prospects: gene therapy clinical trials (part 2)
    Eric Alton
    Department of Gene Therapy, Emmanuel Kaye Building, NHLI, Imperial College, Manresa Road, London, UK
    Gene Ther 14:1555-63. 2007
    ..This part includes clinical trials for skin diseases, neurological disorders, HIV/AIDS, ornithine transcarbamylase deficiency, alpha(1)-antitrypsin deficiency, haemophilia and cancer...
  30. pmc Targeted therapies for pancreatic cancer
    S A Danovi
    Centre for Molecular Oncology and Imaging, Institute of Cancer, Barts and the London School of Medicine and Dentistry, Queen Mary, University of London, London, UK
    Br Med Bull 87:97-130. 2008
    ..Furthermore, early diagnosis represents a serious hurdle for clinicians, as symptoms are non-specific and usually manifest in advanced, treatment-resistant stages of the disease...
  31. ncbi request reprint Inhibiting estrogen responses in breast cancer cells using a fusion protein encoding estrogen receptor-alpha and the transcriptional repressor PLZF
    L Buluwela
    Department of Cancer Medicine, Imperial College London, London, UK
    Gene Ther 12:452-60. 2005
    ..Taken together, these results show that PLZF-ERalpha is a potent repressor of estrogen-regulated gene expression and could be useful in distinguishing estrogen-regulated genes required for the growth of breast cancer cells...
  32. ncbi request reprint Pancreatic cancer genetics
    E Efthimiou
    ICRF Molecular Oncology Unit, Imperial College School of Medicine, Hammersmith Hospital, London, UK
    Pancreatology 1:571-5. 2001
    ..The concept of screening high-risk groups for pancreatic cancer is emerging, preferably in specialised centres with a multidisciplinary team approach...
  33. ncbi request reprint Expression of Smac/DIABLO in ovarian carcinoma cells induces apoptosis via a caspase-9-mediated pathway
    I A McNeish
    Cancer Research UK Molecular Oncology Unit, Imperial College School of Medicine, Hammersmith Hospital, W12 ONN, London, UK
    Exp Cell Res 286:186-98. 2003
    ..Ad CMV-Smac can combine with other proapoptotic factors, such as cisplatin, paclitaxel, and procaspase-3, to produce greater levels of apoptosis in transfected cells...
  34. ncbi request reprint Cellular characterization of the tropism of recombinant adenovirus for the adrenal glands
    Y Wang
    Cancer Research UK, Imperial College, London, UK
    Eur J Clin Invest 33:794-8. 2003
    ..Recombinant adenoviruses are widely used in gene therapy clinical trials. A particular tropism for the adrenal glands has been reported but the precise cellular base for this tropism has not been determined...
  35. ncbi request reprint Prime-boost vaccines encoding an intracellular idiotype/GM-CSF fusion protein induce protective cell-mediated immunity in murine pre-B cell leukemia
    S Pasquini
    ICRF Molecular Oncology Unit, Imperial College School of Medicine, Hammersmith Hospital, London, UK
    Gene Ther 9:503-10. 2002
    ..Both CD4(+) and CD8(+) T cells contributed to protection in vaccinated mice. These data suggest that such a vaccine regimen might reduce the incidence of recurrence in patients with minimal residual disease after conventional therapy...
  36. pmc FGF-1 and FGF-2 modulate the E-cadherin/catenin system in pancreatic adenocarcinoma cell lines
    I el-Hariry
    Imperial Cancer Research Fund Molecular Oncology Unit, Imperial College School of Medicine, London, UK
    Br J Cancer 84:1656-63. 2001
    ..These results demonstrate that FGF-1 and FGF-2 may be involved in the regulation of cell adhesion, differentiation and invasion of pancreatic cancer...
  37. ncbi request reprint Herpesvirus saimiri-based vector biodistribution using noninvasive optical imaging
    P G Smith
    School of Biochemistry and Microbiology, University of Leeds, Leeds, UK
    Gene Ther 12:1465-76. 2005
    ....
  38. pmc Pancreatic cancer cells overexpress gelsolin family-capping proteins, which contribute to their cell motility
    C C Thompson
    Division of Surgery and Oncology, Royal Liverpool University Hospital, 5th Floor UCD Building, Daulby Street, University of Liverpool, Liverpool L68 3 GA, UK
    Gut 56:95-106. 2007
    ..Previously, proteomic methods were applied to characterise differentially expressed proteins in microdissected pancreatic ductal adenocarcinoma cells...
  39. ncbi request reprint Adenovirus-mediated transfer of p53 and p16(INK4a) results in pancreatic cancer regression in vitro and in vivo
    P Ghaneh
    Department of Surgery, University of Liverpool, Liverpool, UK
    Gene Ther 8:199-208. 2001
    ..0001). These results show that transfer of wild-type p53 and p16 produces significant growth suppression of pancreatic cancer in vitro and in vivo...
  40. ncbi request reprint Pro-caspase-3 overexpression sensitises ovarian cancer cells to proteasome inhibitors
    T Tenev
    ICRF Molecular Oncology Unit, Imperial College School of Medicine at Hammersmith Hospital, London W12 ONN, UK
    Cell Death Differ 8:256-64. 2001
    ..Our results demonstrate that pro-caspase-3 can sensitise ovarian cancer cells to proteasome inhibitor-induced apoptosis, and a combination of these approaches might be exploited for therapy of ovarian and other cancers...
  41. pmc Dominant negative inhibitors of signalling through the phosphoinositol 3-kinase pathway for gene therapy of pancreatic cancer
    V Stoll
    Cancer Research UK, Molecular Oncology Unit, Faculty of Medicine, Imperial College London, UK
    Gut 54:109-16. 2005
    ..Ras signalling is frequently aberrant in pancreatic cancer so that there is constitutive activation of the phosphatidylinositol 3-kinase (PI3K) and AKT/protein kinase B pathway, as well as the RAF/MEK/ERK pathway...
  42. ncbi request reprint Adenoviral delivery of TIMP1 or TIMP2 can modify the invasive behavior of pancreatic cancer and can have a significant antitumor effect in vivo
    A S Rigg
    Imperial Cancer Research Fund Molecular Oncology Unit, Imperial College School of Medicine, London W12 0NN, UK
    Cancer Gene Ther 8:869-78. 2001
    ..These experiments have proved the hypothesis that TIMP overexpression in pancreatic cancer cells can modify the invasive phenotype. Also, TIMP gene transfer to human tumor cells is possible both in vitro and in vivo...
  43. ncbi request reprint Genetic profile of 22 pancreatic carcinoma cell lines. Analysis of K-ras, p53, p16 and DPC4/Smad4
    P S Moore
    Department of Pathology, University of Verona, Italy
    Virchows Arch 439:798-802. 2001
    ....
  44. ncbi request reprint Information overload? Take the 'Progress and Prospects' cure
    N J H Campbell
    Gene Ther 9:1343. 2002
  45. ncbi request reprint The power to deliver: stem cells in gene therapy
    N R Lemoine
    Gene Ther 9:603-5. 2002
  46. pmc Conditional immortalization of human thyroid epithelial cells: a tool for analysis of oncogene action
    D Wynford-Thomas
    Department of Pathology, University of Wales, College of Medicine, Health Park, Cardiff, United Kingdom
    Mol Cell Biol 10:5365-77. 1990
    ....
  47. ncbi request reprint UK cash for gene therapy: government pledges support
    N R Lemoine
    Gene Ther 10:1405-6. 2003
  48. ncbi request reprint Imbalance of expression of matrix metalloproteinases (MMPs) and tissue inhibitors of the matrix metalloproteinases (TIMPs) in human pancreatic carcinoma
    S R Bramhall
    Department of Surgery, City Hospital NHS Trust, Birmingham, U K
    J Pathol 182:347-55. 1997
    ....
  49. ncbi request reprint Gene expression profiles of progressive pancreatic endocrine tumours and their liver metastases reveal potential novel markers and therapeutic targets
    G Capurso
    Digestive and Liver Disease Unit, II Medical School, University La Sapienza, Rome, Italy
    Endocr Relat Cancer 13:541-58. 2006
    ..The analysis of liver metastases revealed a previously unknown high level of similarity with the primary lesions...
  50. ncbi request reprint Expression profile of survivin in acute leukaemias: the importance of differential splicing
    R Lopes
    Leukemia 19:1284-6. 2005
  51. ncbi request reprint FGF-1 and FGF-2 regulate the expression of E-cadherin and catenins in pancreatic adenocarcinoma
    I el-Hariry
    Imperial Cancer Research Fund Molecular Oncology Unit, Imperial College School of Medicine, Hammersmith Campus, London, United Kingdom
    Int J Cancer 94:652-61. 2001
    ..These findings indicate that the E-cadherin/catenin system is a target of the FGF/FGFR system and that coordinated signals from both systems may determine the ultimate biologic responses...
  52. ncbi request reprint Non-random chromosomal rearrangements in pancreatic cancer cell lines identified by spectral karyotyping
    V Sirivatanauksorn
    Imperial Cancer Research Fund Molecular Oncology Unit, Imperial College School of Medicine, Hammersmith Hospital, London, United Kingdom
    Int J Cancer 91:350-8. 2001
    ..The observation that loss at 11q and gains at 5p with i(5)(p10) and 12p with i(12)(p10) are more frequent changes than previously reported would justify more intensive investigation of these chromosomal regions...